Business Wire

Neomorph, Inc. Announces $109 Million Series A Financing to Advance Proprietary Protein Degradation Platform and Programs

SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc. announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. Deerfield Management ...
manilatimes

Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the first patient ...
Business Wire

Neomorph, Inc. Announces Appointment of Chief Financial Officer

SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ...
manilatimes

Neomorph Appoints Biopharma Leader Robert J. Hugin as Chairman of the Board

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company advancing a new class of molecular glue degraders to target historically undruggable proteins, today announced the ...